Lv1
30 积分 2024-07-18 加入
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
2天前
已完结
Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study
3个月前
已完结
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
3个月前
已完结
Colorectal cancer
3个月前
已完结
Precision treatment in advanced hepatocellular carcinoma
3个月前
已完结
Antibody–drug conjugates for cancer
3个月前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
3个月前
已完结
Cancer therapy with antibodies
3个月前
已完结
Antibody–drug conjugates come of age in oncology
3个月前
已完结
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation
3个月前
已完结
皖公网安备34019202002308
